Background. Pulmonary haemorrhage (PH) is a serious manifestation of systemic vasculitis with high mortality rates yet vasculitis is associated with an increased prevalence of venous thromboembolism (VTE). The concurrent presentation of severe PH and VTE poses a challenge in terms of therapeutic management. Methods. This is a retrospective case review of the clinical manifestations and response to treatment in vasculitis patients presenting with concurrent pulmonary haemorrhage and VTE ( pulmonary embolism and/or deep venous thrombosis). Results. Of 35 patients with severe PH due to systemic vasculitis, 7 (20%) had concurrent VTE. The most common cause was anti-neutrophil cytoplasm antibody-associated vasculitis, followed by anti-glomerular basement membrane disease. Vasculitis responded to conventional therapies and VTE treatment with anticoagulation was uncomplicated in five of six cases. In one case, anticoagulation precipitated the PH and another was not anticoagulated and developed recurrent VTE. All patients survived without further complications after a mean follow-up of 46 months (3-98). Conclusions. Concurrent VTE occurred in one-fifth of cases with severe PH due to vasculitis. Management of VTE with anticoagulation was effective but led to pulmonary haemorrhage in one patient.
Introduction
Pulmonary haemorrhage (PH) is a potentially life-threatening manifestation of systemic vasculitis and requires aggressive treatment. The most common causes are antineutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) and antiglomerular basement membrane (GBM) disease [1, 2] . Venous thromboembolism (VTE) is a frequent complication of systemic vasculitis that poses a challenge in therapeutic management when it occurs in patients with active haemorrhage [3, 4] . We describe the frequency and management of this presentation in a cohort of patients with systemic vasculitis.
Materials and methods
Sequential patients with severe PH due to vasculitis referred to our department were retrospectively reviewed and those with VTE [ pulmonary embolus (PE) or deep venous thrombosis (DVT)] occurring in the month prior to or during an episode of PH were further studied. The diagnoses of AAV and anti-GBM disease accorded with the definitions of the 1993 Chapel Hill Consensus Conference and diagnostic criteria of the European Vasculitis Study Group. The case with vasculitis secondary to the anti-synthetase syndrome was diagnosed by lung biopsy. Diagnosis of severe PH required bilateral diffuse alveolar infiltrates on chest X-ray or computed tomography (CT) scan combined with haemoptysis and dyspnoea, supported by either (i) >2 g/dL fall in haemoglobin, (ii) alveolar haemorrhage on bronchoscopy and bronchoalevolar lavage or (iii) hypoxaemic respiratory failure, without other explanation. In accordance with UK National Health Service Research Ethics Committee guidelines, ethical approval was not required for this work.
Results
Thirty-five patients with severe PH secondary to vasculitis were reviewed, of which 7 (20%) had VTE (Table 1 ). In six, the index episode of PH and VTE was the initial disease presentation. AAV was diagnosed in four (57%), anti-GBM disease in two (43%) and anti-synthetase syndrome in one (Table 1) . Identified risk factors for VTE included obesity in three, smoking in four, pregnancy in one and a family history of VTE in one. Screening for proteins C and S, anti-thrombin deficiency and activated protein C resistance was negative in three of three cases and anti-cardiolipin and anti-β 2 -glycoprotein 1 antibodies were absent in four of four cases tested.
PH presented with haemoptysis and dyspnoea in all seven, haemoglobin drop >2 g/dL in four and hypoxaemic respiratory failure in three. Radiographs revealed new alveolar infiltrates in all ( Figure 1a) . Five had the diagnosis confirmed by bronchoscopy and bronchoalveolar lavage. are summarized in Table 2 . No patient had coagulopathy or critical thrombocytopaenia (<50 000 cells/mm 3 ). Therapy of vasculitis is described in Table 3 with four receiving plasma exchange (PEx). Anticoagulation was started after the VTE diagnosis in five and after a delay of 7 days in one (Table 3) . One case did not receive anticoagulation and an inferior vena caval (IVC) filter was inserted. One case developed PH 2 weeks after initiation anticoagulation for VTE; this case received PEx for PH and anticoagulation was maintained with low-molecularweight heparin (LMWH). Four had an IVC filter inserted including the case with delayed anticoagulation.
All patients survived after a median follow-up of 46 months (range 3-98). A subsequent PE occurred in the patient who did not receive anticoagulation and was later treated with LMWH for 6 months. There were no further episodes of haemorrhage. Long-term anticoagulation was prescribed only for repeated VTE. Pulmonary fibrosis present at the time of vasculitis diagnosis in two was not observed in the others during follow-up.
Discussion
The frequency of PH in AAV and anti-GBM disease is 24 and 50%, respectively [5, 6] . There is an increased risk of VTE in AAV patients with a reported incidence of 7.0 per 100 person-years in granulomatosis with polyangiitis (Wegener's) associated with active disease [7] . There is one reported case of concurrent VTE and PH in vasculitis where anticoagulation led to worsening of PH [4] .
We found a 20% incidence of VTE in severe PH indicating the clinical importance of this association. The majority were initial disease presentations that responded appropriately to conventional therapies including PEx. No worsening of PH occurred in five of six patients anticoagulated preventing further VTEs, except in one case where anticoagulation precipitated the PH, so the benefits of anticoagulation must be balanced against the potential risk of haemorrhagic complications.
The higher incidence of VTE in AAV is not related to the presence of classical risk factors [8] [9] [10] . Inflammation of the vessel wall, caused by local ANCA-induced neutrophil activation, is a potential mechanism [11, 12] . The recent identification of autoantibodies to plasminogen to tissue plasminogen activator in AAV, with in vitro potential to retard fibrinolysis, may also explain the increased thrombotic risk [13] .
The combination of conventional immunomodulatory therapy with anticoagulation was effective for both PH and VTE pathologies, leading to haemorrhagic complications in only one case. Intracaval filters did not obviate the need for anticoagulation but are an option if anticoagulation is delayed. Long term outcomes were good in all patients. 
